Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathological Characterisation of Posterior Cortical Atrophy in Comparison With Amnestic Alzheimer's Disease.

Neuropathology and applied neurobiology·2025
Same author

Disruption of macroscale functional network organisation in patients with frontotemporal dementia.

Molecular psychiatry·2024
Same author

Distinct spatiotemporal atrophy patterns in corticobasal syndrome are associated with different underlying pathologies.

medRxiv : the preprint server for health sciences·2024
Same author

A data-driven model of brain volume changes in progressive supranuclear palsy.

Brain communications·2022
Same author

AD and its comorbidities: An obstacle to develop a clinically efficient treatment?

Revue neurologique·2022
Same author

Not all voxels are created equal: Reducing estimation bias in regional NODDI metrics using tissue-weighted means.

NeuroImage·2021

Related Experiment Video

Updated: Jun 5, 2026

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

Primary progressive aphasia: defining genetic and pathological subtypes.

J D Rohrer1, J M Schott

  • 1Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK. rohrer@dementia.ion.ucl.ac.uk

Current Alzheimer Research
|January 13, 2011
PubMed
Summary

Primary progressive aphasias (PPA) are diverse neurodegenerative disorders. Accurately diagnosing PPA pathology during life is crucial for developing effective treatments and clinical trials.

More Related Videos

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models
08:33

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models

Published on: March 24, 2019

Related Experiment Videos

Last Updated: Jun 5, 2026

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models
08:33

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models

Published on: March 24, 2019

Area of Science:

  • Neurology
  • Neuroscience
  • Pathology

Background:

  • Primary progressive aphasias (PPA) represent a heterogeneous group of neurodegenerative conditions.
  • PPA is pathologically defined by frontotemporal lobar degeneration with tau (FTLD-tau), TDP (FTLD-TDP), or Alzheimer's disease (AD) pathology.
  • Current clinical classification includes semantic, logopenic, and nonfluent variants, with ongoing debate regarding subtype dissection.

Purpose of the Study:

  • To review the genetic and pathological underpinnings of PPA.
  • To emphasize the growing importance of accurate in-life pathological diagnosis for PPA clinical trials.
  • To survey current and emerging biomarkers for diagnosing PPA-tau, PPA-TDP, and PPA-AD.

Main Methods:

  • Literature review of genetic and pathological bases of PPA.
  • Analysis of clinical and neuropsychological data relevant to PPA subtypes.
  • Evaluation of neuroimaging, blood, and cerebrospinal fluid (CSF) biomarkers.

Main Results:

  • PPA heterogeneity stems from distinct underlying pathologies (FTLD-tau, FTLD-TDP, AD).
  • Accurate pathological diagnosis is essential for targeted therapeutic development.
  • Biomarkers are key to differentiating PPA subtypes in vivo.

Conclusions:

  • Accurate in-life pathological diagnosis of PPA is critical for advancing clinical trials.
  • A combination of clinical, imaging, and fluid biomarkers will facilitate PPA subtyping.
  • Future research should focus on refining biomarkers for precise PPA pathology identification.